App-Quantinova.ai

Enhancing quality improvement capacity through the British Society for Rheumatology’s multi-region audit into the management of adults with systemic lupus erythematosus

Charlotte A Sharp - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Respiratory involvement in relapsing polychondritis: a single centre study

Catherine D Hughes - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Relapsing polychondritis

N/A

Population demographics and clinical assessment from the BSR multi-region audit on the management of adults with SLE lend a unique insight into SLE in the UK

Nehal Narayan - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

The prevalence and impact of fatigue and physical activity in people with primary antiphospholipid syndrome: a mixed methods study

Lindsay M Bearne - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Antiphospholipid syndrome

N/A

Cognitive dysfunction in systemic lupus erythematosus: is there a contribution from cardiovascular risk factors?

Michelle Barraclough - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Does the new (preliminary) American College of Rheumatology/European League Against Rheumatism classification criteria set provide prognostic information about the outcome in systemic lupus erythematosus?

Antonio Costa Carneiro - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Why do some patients with systemic lupus erythematosus fail to respond to B cell depletion using rituximab?

Sara C M Freitas - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Rituximab

BSR multi-region audit on the management of adults with systemic lupus erythematosus 2018: compliance with audit standards

Rebecca Batten - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Belimumab

Secondary adrenal insufficiency in patients with systemic lupus erythematosus: active management of steroid withdrawal reduces risk of disease flare

Haroon Ahmed - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Prednisolone

Baseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR)

Sophie Collinson - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus nephritis

Rituximab

Exploring factors associated with increased rates of respiratory infections in SLE and vasculitis patients

Andrea Guida - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Infliximab

Targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE): results from a proof-of-concept phase II trial

Md Yuzaiful - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Etanercept

Remission/low disease activity is an achievable treatment target in psoriatic arthritis (PsA): results from a routine care European cohort of PsA patients treated with ustekinumab or TNF inhibitors

Stefan Siebert - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Ustekinumab

Safety and effectiveness of certolizumab pegol in axial spodyloarthritis in a real-world setting: a UK sub-analysis from a European non-interventional study

Helena Marzo-Ortega - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

Certolizumab pegol

Sustained improvements in disease activity for up to two-years with ixekizumab in patients with active psoriatic arthritis who were either biologic-naïve or with previous inadequate response to tumour necrosis factor inhibitor therapy

Deepak R Jadon - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Adalimumab

Would stratifying MRI requests improve efficiency in patients with suspected axial spondyloarthritis?

Priam Heire - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Rapid and sustained improvements in patient-reported outcomes with ixekizumab in biologic-naïve and TNF-inadequate responder patients with psoriatic arthritis

Hasan Tahir - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

LY2439821

The prevalence of axial involvement in psoriasis or psoriatic arthritis: a systematic review and meta-analysis

Jeeu Teck Sze - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

N/A

Performance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review

Alexis Jones - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from FUTURE 2 AND FUTURE 3 Phase 3 studies

Iain B McInnes - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

Filters

45280 Abstracts